I t is estimated that almost 6 million Americans are currently living with heart failure (HF), a number that is projected to exceed 8 million by 2030. 1 As a result of the high prevalence and substantial morbidity and mortality associated with HF, the financial burden to the healthcare system is enormous, with an estimated annual cost of $31 billion in the United States. 1 Accordingly, preventing HF is integral to improving population health and reducing financial costs, which is reflected by the emphasis on prevention in recent HF practice guidelines. 2,3
CVH Score and Heart Failure Incidence including abstinence from smoking, ideal body mass index (BMI), regular physical activity, healthy diet, low untreated serum total cholesterol concentrations, optimal BP, and absence of diabetes mellitus. 12 Together, these components comprise CVH, which is inversely associated with the risk of CVD and overall mortality in multiple reports. [13] [14] [15] [16] However, the relationship between CVH and HF has not been systematically assessed. We therefore hypothesized that CVH is inversely associated with the risk of incident HF, and that this association is partly attributable to the inverse association of CVH with the prevalence of adverse cardiac remodeling.
Methods

Study Sample
The descriptions of the history, design, and methodology of the Framingham Offspring Study (FOS) have been reported elsewhere. 17 For this investigation, 3532 FOS participants attending the sixth examination cycle (1995) (1996) (1997) (1998) were considered for inclusion, and 2 distinct samples were evaluated for analysis of echocardiographic traits and incidence of HF, respectively, as detailed below. At the sixth examination cycle (referred to as baseline for the present investigation), all attendees underwent a medical history, anthropometry, a cardiovascular-targeted physical examination, electrocardiography, echocardiography, and phlebotomy for measurement of standard cardiovascular risk factors at the Framingham Heart Study (FHS) clinic. Of 3532 attendees, we initially excluded participants for serum creatinine concentration ≥2 mg/dL (n=15), BMI <18.5 kg/m 2 (n=62), missing components of the CVH score (n=219), or outlier laboratory values (n=1), yielding a base sample of 3235 participants. To evaluate the association between CVH and echocardiographic indices of cardiac remodeling, additional exclusions were made from the base sample for missing echocardiographic measurements (n=843), resulting in a sample of 2392 participants (sample 1). For evaluating the association between CVH and incident HF, we excluded from the base sample people with prevalent HF (n=30) and nonavailable follow-up time (n=4), resulting in a sample of 3201 participants (sample 2); this sample was larger because availability of echocardiographic measurements was not required for relating CVH score to incident HF. The Boston University Medical Center Institutional Review Board approved all study protocols. Written informed consent was provided by all participants.
AHA CVH Score
A CVH score was constructed for each participant by assigning a score of 0 (poor status), 1 (intermediate status), or 2 (ideal status) for each of the 7 metrics of CVH ( Table I in the Data Supplement). The CVH score was obtained by summing these values and it can thus vary from a minimum of 0 (consistent with poor CVH) to a maximum of 14 (indicating ideal CVH). Resting BP, BMI, cholesterol, fasting blood glucose, and self-reported smoking status were measured at the FHS clinic. The physical activity index was calculated as the sum of the reported time spent performing specific physical activities during a 24-hour period as previously described. 16, 18 The highest quartile of this index was used to define ideal physical activity, and values higher than the median but less than the top quartile were used to define intermediate status. Dietary quality was assessed using a food frequency questionnaire ( Table I in the Data Supplement). In agreement with previous investigations, a score of ≥2 was considered to be ideal status, 1 was considered intermediate status, and 0 was considered poor status. 14, 19 
Echocardiographic Measurements
All attendees at the sixth FOS examination cycle (1995-1998) underwent comprehensive 2-dimensional (2D) transthoracic echocardiography with Doppler color flow imaging as described previously. 20 Echocardiograms were read by a sonographer or a cardiologist who was blinded to clinical information. M-mode measurements, averaged over ≥ 3 cardiac cycles, were obtained from digitized images using the leading edge-to-leading edge technique for LAD, end-diastolic LV septal wall thickness, posterior wall thickness, and LV diameter at the end of diastole (LVDD) and LV diameter at the end of systole. Fractional shortening (FS) was calculated as: ([LVDD−LV diameter at the end of systole]/LVDD)×100, LV wall thickness was calculated by summing LV septal wall thickness and posterior wall thickness in end-diastole, and relative wall thickness (RWT) was obtained by dividing LV wall thickness by LVDD. We calculated LVM using the formula: LVM=0.8(1.04[{LVDD+posterior wall thickness+septal wall thickness} 3 −{LVDD} 3 ])+0.6, based on American Society of Echocardiography (ASE) guidelines. 21 LV hypertrophy was determined by indexing the LVM to body surface area, and values >115 g/m 2 for men and >95 g/m 2 for women were considered abnormal. 21 LV systolic dysfunction (LVSD) was defined by FS <29% or by mild or greater reduction in ejection fraction based on qualitative assessment. Using ASE cut points for normal LVM (≤115 g/m 2 for men and ≤95 g/m 2 for women) and the normal RWT cut-point of ≤0.42, 21 geometric patterns were defined as: normal geometry (normal LVM and RWT), concentric remodeling (normal LVM and increased RWT), concentric hypertrophy (increased LVM and RWT), and eccentric hypertrophy (increased LVM and normal RWT), Table II in the Data Supplement.
Outcome Events
Participants were followed continuously throughout the study period for the incidence of CVD events including HF, which was defined using the FHS criteria. 22 In brief, ascertainment of HF requires the presence of 2 major or 1 major and 2 minor criteria; major criteria include paroxysmal nocturnal dyspnea or orthopnea, increased venous pressure, distended neck veins, rales, cardiomegaly by radiograph, pulmonary edema, a third heart sound, hepatojugular reflux, and weight loss on diuretic therapy. The presence of ankle edema, nocturnal cough, hepatomegaly, dyspnea on exertion, pleural effusion, decrease in vital capacity, and tachycardia comprise the minor criteria. Medical records were obtained for all physician visits and hospitalizations related to CVD, and events were adjudicated by a review committee of 3 FHS physicians. The date of onset of HF was determined by the earliest onset of symptoms, or the date of hospitalization or clinic visit. In secondary analyses, we assessed the associations between CVH score and HF subtype after categorizing HF events as HF with reduced ejection fraction (HFREF) if the ejection fraction was <45% and HF with preserved ejection fraction (HFPEF) if the ejection fraction was ≥45% based on echocardiographic reports from the index hospitalization.
Statistical Analysis
In both samples, the predictor of interest was the CVH score, which was modeled as a continuous variable in all primary analyses. Using sample 1, we examined the cross-sectional relations of the CVH score with (1) the following echocardiographic indices: LVM, LVDD, LV wall thickness, LAD, and FS in age-and sex-adjusted linear regression models; (2) the presence of LVSD and LV hypertrophy in ageand sex-adjusted logistic regression models (both binary variables); and (3) the presence of 4 LV geometric patterns (normal geometry, concentric remodeling, concentric hypertrophy, and eccentric hypertrophy) in age-and sex-adjusted multinomial logistic regression models using generalized logits treating those with normal geometry as the referent group.
Using sample 2, we evaluated the prospective association between the CVH score and HF incidence using age-and sex-adjusted Cox proportional hazard regression models, after confirming that the assumption of proportionality of hazards was met. In secondary analyses, we examined the relations of CVH score with the incidence of HFPEF and HFREF (separate analyses for each). Fine-Gray proportional hazard models were used to account for competing risks, including the HF subtype not modeled, and indeterminate HF events (ie, HF with unavailable EF). We examined penalized cubic splines to CVH Score and Heart Failure Incidence assess for potential nonlinearity of the associations of the CVH score with HF, and with each of the HF subtypes.
In further secondary analyses, the CVH score was modeled in categories with grouping of 0 to 7, 8 to 9, and 10 to 14 (to provide approximate tertiles), treating the lower CVH tertile (scores, 0-7) as the referent. We also analyzed the CVH score as a 7-point score with each of the 7 AHA metrics considered as a binary variable. Sensitivity analyses were performed after removing the hypertension metric from the CVH score, thus constructing a score with a maximum value of 12 points. Statistical significance was assessed based on a 2-sided P value of <0.05. The SAS Software version 9.3 (Cary, NC) was used for all analyses. The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the article as written.
Results
The baseline characteristics of the larger sample (sample 2) are shown in Table 1 . Participants were mostly middle-aged and overweight with a high prevalence of hypertension. Ideal CVH was present in a small proportion of participants (Figure 1 ). Characteristics were similar in sample 1 (Table III and 
Association Between CVH Score and Echocardiographic Traits
In cross-sectional analyses, statistically significant associations between the CVH score and several echocardiographic measures were observed ( Table 2) . LVM was inversely associated with CVH score, in concordance with its 2 primary components: LV wall thickness and LVDD. LAD also demonstrated an inverse association with the CVH score. No statistically significant associations were observed between the CVH score and FS, LVSD, or LV hypertrophy.
Association Between CVH Score and Geometric Patterns of Cardiac Remodeling
Normal LV geometry was present in 1283 participants (54%), concentric remodeling in 486 (20%), eccentric hypertrophy in 352 (15%), and concentric hypertrophy in 271 (11%). Each 1-point higher CVH score was associated with a 12% and 15% lower odds of concentric remodeling and concentric hypertrophy, respectively, compared with the normal geometric pattern (Table 3 ). When the CVH score was analyzed according to categories, the higher CVH category (score, 10-14) had 42% and 54% lower odds of concentric remodeling and concentric hypertrophy, respectively, when compared with the lower CVH category (score, 0-7; P<0.01 for both), Table IV in the Data Supplement. We did not observe a statistically significant association between the CVH score (continuous or categorical) and the odds of eccentric hypertrophy.
Association Between CVH Score and HF Incidence
A total of 3201 participants were followed for ≤16 years (mean, 12.3 years) and 188 individuals developed HF (5.9%). The CVH score was inversely associated with incident HF (Figure 2 ). For each 1-point higher CVH score, we observed a 23% lower risk of HF, adjusting for age and sex (Table 4 ). When the CVH score was modeled as a categorical variable, the HF hazard ratio for CVH scores of 8 to 9 and 10 to 14 was 45% and 66% lower, respectively, when compared with scores of 0 to 7 ( Table V in the Data Supplement). The effect of CVH score on incident HF was partially attenuated when further adjusted for LVM and interim myocardial infarction (Table 4 models 2-4), which occurred in 250 participants (7.8%). This partial attenuation is reflected by a 35% change in the parameter estimate corresponding to the CVH score (β=−0.26 in the model adjusted for age and sex as compared with β=−0.17 in the model adjusted for age, sex, interim MI, and LVM). Further adjustments for B-type natriuretic peptide and urine albumin/creatinine ratio did not result in additional attenuation (Table 4, model 5).
Association Between CVH Score and HF Subtype
Of the 188 participants with incident HF, 85 (45.2%) developed HFPEF, 89 (47.3%) developed HFREF, and in 14 (7.5%) subjects the HF subtype was indeterminate because of an unavailable EF. Using Fine-Gray Proportional Hazard models to adjust for competing risks, the relations of the CVH score with incident HF did not vary significantly by HF subtype ( Table 5 ; Figure II in the Data Supplement). When adjusted for interim MI, the relation between the CVH score and the HFPEF remained essentially unchanged (β=−0.22 for model adjusted for age and sex as compared with β=−0.23 in the model adjusted for age, sex, and interim MI), whereas the association of CVH score and incident HFREF was mildly attenuated (β=−0.27 for model adjusted for age and sex as compared with β=−0.21 in the model adjusted for age, sex, and interim MI).
In secondary analyses, the CVH score was modeled in categories and as a 7-point score without notable differences *Sample size for the biomarker evaluation was 2046. CVH Score and Heart Failure Incidence from these findings (data not shown). In addition, we performed a sensitivity analyses after removing the hypertension metric from the CVH score (thus creating a 12-point CVH score), and the results were essentially unchanged (Tables  VI-IX in the Data Supplement) .
Discussion
Principal Findings
The principal findings of our report are 2-fold. First, CVH was inversely associated with the prevalence of several echocardiographic traits and with concentric forms of LV geometric patterns cross-sectionally. Second, CVH was inversely associated with HF incidence prospectively, a relation that was consistent among the HF subtypes of HFPEF and HFREF, and it was partly attributable to the inverse association of CVH with the presence of adverse LV remodeling.
Comparison With Previous Studies
Ideal CVH was rare in our sample, consistent with findings from other community-based cohorts. [13] [14] [15] [16] 23, 24 Previous reports have demonstrated associations between CVH and a reduced incidence of cardiovascular outcomes, including stroke, 15 cardiovascular death, 14, 23 and the composite of CVD. 13, 16, 25, 26 Several studies have demonstrated the beneficial effects of a healthy lifestyle on reducing HF incidence. 6, 7, 27 However, these investigations focused primarily on 4 of the 7 components of the CVH score, namely: abstinence from smoking, BMI ≤25 kg/m 2 , physical activity, and healthy diet, with 1 study also including alcohol consumption. In each of these previous reports, there was a graded and stepwise association between the positive behavior or risk factor value achieved and a reduced risk of HF. Similarly, in our study we found that each point achieved in the CVH score was associated with a lower incidence of HF. Furthermore, we observed that this association was true for both HFPEF and HFREF; previous reports did not examine the association of CVH with HF subtypes.
Mechanisms Underlying the Association of CVH With a Reduction in HF Incidence
There are several plausible pathomechanisms responsible for the increased risk of HF in those with poor CVH. First, poor CVH is known to promote atherosclerotic vascular disease 16, 25 and, therefore, may lead to clinical HF via reductions β coefficient values represent the mean change in echocardiographic measurement per 1-point higher CVH score. Odds ratios represent the odds of having the echocardiographic trait for each 1-point higher CVH score versus not having the trait. CVH indicates cardiovascular health; and LV, left ventricular. CVH Score and Heart Failure Incidence in ventricular systolic and diastolic function as a result of MI. Although this sequence of events is frequently encountered in clinical practice, the association between the CVH score and HF incidence was only mildly affected by adjusting for interim MI in our study. However, when HF incidence was assessed according to HF subtype, we did observe that the magnitude of association between the CVH score and HFREF was slightly attenuated after adjusting for interim MI, whereas the association between CVH score and HFPEF was unchanged. This is consistent with previous observations that ischemic heart disease is more closely related to incident HFREF than HFPEF. Certainly, subclinical ischemic heart disease resulting in reduced cardiac function without overt MI is another possible mechanism linking incident HF with poor CVH that was not assessed by this study.
Alternatively, our findings support a second plausible pathomechanism that poor CVH promotes a program of adverse cardiac remodeling that begins as subclinical changes in cardiac structure and function (AHA/American College of Cardiology stage B HF) and eventually progresses to clinical HF (AHA/American College of Cardiology stage C HF). In our study, a lower CVH score was associated with higher LVM and LAD, and higher odds of having concentric remodeling or concentric hypertrophy. These abnormalities are associated with incident HF and may suggest a mechanistic link between the CVH score and HF incidence. This notion is further supported by the attenuation of the association between CVH score and incident HF when adjusted for LVM, suggesting that increased LVM partially attenuates the relation.
Traditional cardiovascular risk factors leading to clinical HF via subclinical remodeling is biologically plausible and, Values represent the odds of having the geometric pattern for each 1-point higher CVH score compared with the normal geometric pattern. CI indicates confidence interval; CVH, cardiovascular health; LV, left ventricular; and OR indicates odds ratio. Figure 2 . A, Cumulative incidence of heart failure (HF) according to cardiovascular health (CVH) score (modeled as categories). B, Age-, and sex-adjusted association between CVH score (modeled as a continuous variable) and HF incidence. CVH Score and Heart Failure Incidence indeed, several of the components of the CVH score have been individually associated with both clinical HF and adverse cardiac remodeling. Increased LVM, for example, is strongly associated with the presence of hypertension, diabetes mellitus, obesity, physical inactivity and smoking, 28, 29 whereas left atrial dilatation correlates with increasing age, BMI, elevated systolic BP and the use of antihypertensive medications. 30 Concentric geometric patterns of LV remodeling seem to be more related to the presence of hypertension and diabetes mellitus, whereas eccentric patterns may correlate more strongly with elevated BMI. 31 Our data seem consistent with these findings, suggesting that the CVH score may be an important correlate of cardiac structure and geometry.
However, the associations of the CVH score with incident HF remain statistically significant after adjustment for LVM and other important HF predictors, such as interim MI, B-type natriuretic peptide, and urine albumin/creatinine ratio. These findings suggest that CVH may also be related to HF incidence independently of cardiovascular remodeling and MI. Therefore, a third plausible explanation for the observed association of CVH with HF incidence involves the positive effects of CVH on other organ systems or other components of the cardiovascular system. Endothelial dysfunction and vascular stiffness, for example, are known precursors of HF that may be impacted by CVH. We did not have measures of vascular stiffness at the sixth FOS examination cycle to examine this premise. Furthermore, the CVH score has been related to biomarkers of select biological pathways (such as B-type natriuretic peptide, Growth Differentiation Factor-15, inflammation, renin-angiotensin-aldosterone pathway 16 ) and the latter have been implicated in mediating HF risk. 32, 33 The CVH score may also be related to noncardiovascular predictors of HF, such as altered lung or renal function. 34 A detailed exploration of these possibilities was beyond the scope of our present investigation. These and other novel mechanisms linking CVH with HF incidence are also possible and warrant further investigation in future reports.
Given the powerful effect of CVH score on incident HF, it is perhaps intriguing that relations were not observed between CVH score and FS, LVSD or eccentric hypertrophy. One potential explanation is that ischemic heart disease, which is more likely to lead to changes in ventricular function, LVSD, and eccentric remodeling was relatively uncommon in our middle-aged sample. In addition, the biological mechanisms underlying the associations of the CVH score with LV systolic function might be more complex than the mechanisms linking the CVH score with concentric hypertrophy. This notion is supported by data from the Multiethnic Study of Atherosclerosis (MESA) cohort, in which Heckbert et al 28 reported that ejection fraction increased with higher systolic BP until a critical point (≥180 mm Hg) after which it demonstrated an inverse relationship. Diastolic BP, in contrast, was inversely associated with ejection fraction throughout its range of values. 28, 35 The CVH score does not take into account this level of complexity. For example, 2 individuals would both be assigned 0 points for the BP metric even if 1 had a BP of 140/90 mm Hg and the other had a BP of 190/120 mm Hg. In addition, we used relatively crude measures of LV pump function and not more sophisticated measures of myocardial performance (such as strain rate imaging, diastolic function, torsion, and synchronicity, all of which may contribute to HF risk and may be potentially related to the CVH score).
Strengths and Limitations
This study was performed in a large community-based sample under continuous surveillance for clinical outcomes (including HF) during a long period of follow-up. Our findings are consistent with previous reports of the relation between traditional cardiovascular risk factors and HF incidence and extend this knowledge by specifically evaluating the impact of the CVH score on HF incidence, by analyzing the HF subtypes (HFPEF and HFREF) separately, and by examining a wide range of echocardiographic measures of cardiac remodeling.
However, several limitations also merit consideration. Our sample included predominantly white, middle-aged participants of European ancestry with a high prevalence of hypertension, potentially limiting the generalizability of our findings to other age groups and ethnicities with differing risk factor distributions. In addition, the exposure (CVH score) was assessed at a single examination and, therefore, changes in the score over time could not be assessed. Similarly, the cross-sectional nature of the echocardiographic measurements limits our ability to track changes in the indices over time and may lead to a regression dilution bias, which would be expected to result in an underestimation of the true underlying associations of CVH Values represent HRs for each 1-point higher CVH score. BNP indicates B-type natriuretic peptide; CI, confidence interval; CVH, cardiovascular health; HF, heart failure; HR indicates hazard ratio; LVM, left ventricular mass; MI, myocardial infarction; and UACR, urine albumin/creatinine ratio.
*Because of unavailability of biomarker measurements in many participants, the sample size for this model included 2046 participants. When tested in this smaller sample, the results for the other models were unchanged. CVH Score and Heart Failure Incidence with echocardiographic traits and with HF. We used M-mode echocardiography rather than 2D measurements and determined left atrial size by diameter rather than volume, both of which are potential limitations. Finally, the definitions used for diet and physical activity were extrapolated from data available from questionnaires completed at the clinical examinations and differ slightly from the AHA metrics. 16 
Conclusions and Future Directions
Better CVH was associated with a lower risk of HF incidence in our large community-based sample. This association was probably at least partially attributable to a lower prevalence of adverse cardiac remodeling in those with a high CVH score. Further studies are warranted to evaluate the biological mechanisms underlying the associations between CVH and adverse cardiac remodeling, as well as to assess the role for potential interventions (behavioral and pharmacological) that might assist in preventing or delaying HF events in higher risk populations. Although observational, our findings provide evidence that targeting strategies to improve CVH in the community (using the CVH score as a metric) may potentially reduce the prevalence of subclinical HF stages (stage B) and perhaps overt HF as well. 
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